MDxHealth SA Ordinary Shares (MDXH)
MDxHealth SA is a medical technology company specializing in the development and commercialization of advanced molecular diagnostic tests for the detection and management of prostate and bladder cancers. Leveraging genomic biomarkers, the company aims to enhance personalized treatment decisions and improve patient outcomes in urology.
Company News
MDxHealth has completed the acquisition of Exosome Diagnostics from Bio-Techne for $15 million, which includes the ExoDx Prostate test and related assets, with payments structured over four years.
MDxHealth appointed Michael Holder to its Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. CFO Ron Kalfus is resigning, with Scott McMahan assuming interim CFO responsibilities.
Agiliti (AGTI) delivered earnings and revenue surprises of 8.33% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?